Menu Search
Equities

Ultragenyx Pharmaceutical Inc

UP0:DEU

Ultragenyx Pharmaceutical Inc

Actions
  • Price (EUR)44.00
  • Today's Change0.40 / 0.92%
  • Shares traded0.00
  • 1 Year change+22.91%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Ultragenyx Pharmaceutical Inc grew revenues 19.52% from 363.33m to 434.25m while net income improved from a loss of 707.42m to a smaller loss of 606.64m.
Gross margin86.25%
Net profit margin-106.93%
Operating margin-102.49%
Return on assets-40.27%
Return on equity-295.34%
Return on investment-50.12%
More ▼

Cash flow in USDView more

In 2023, Ultragenyx Pharmaceutical Inc increased its cash reserves by 59.45%, or 81.80m. Cash Flow from Financing totalled 388.14m or 89.38% of revenues. In addition the company used 474.81m for operations while cash from investing totalled 168.00m.
Cash flow per share-6.03
Price/Cash flow per share--
Book value per share3.76
Tangible book value per share1.49
More ▼

Balance sheet in USDView more

Ultragenyx Pharmaceutical Inc uses little or no debt in its capital structure.
Current ratio2.81
Quick ratio2.65
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.